

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LEPU BIOPHARMA CO., LTD.
樂普生物科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2157)

**POLL RESULTS OF THE 2022 ANNUAL GENERAL MEETING AND
CLASS MEETINGS HELD ON JUNE 15, 2023**

References are made to the notices (the “**Notices**”) and the circular (the “**Circular**”) of the 2022 annual general meeting (the “**AGM**”), the 2023 first class meeting of H Shareholders (the “**Class Meeting of H Shareholders**”) and the 2023 first class meeting of Domestic Shareholders (the “**Class Meeting of Domestic Shareholders**”) of the Company both dated May 24, 2023. Capitalised terms used herein shall have the same meanings as those defined in the Notices and the Circular unless the context requires otherwise.

ATTENDANCE AT THE AGM AND THE CLASS MEETINGS

The AGM was chaired by Dr. Pu Zhongjie, the chairman of the Board and an executive Director, and was successfully held at Conference Room, Building 7, No. 37 Chaoqian Road, Changping District, Beijing, the PRC on Thursday, June 15, 2023 at 10:30 a.m.. The Class Meeting of H Shareholders and the Class Meeting of Domestic Shareholders (collectively the “**Class Meetings**”) were successfully held immediately after the conclusion of the AGM, respectively on the same date and at the same venue. The AGM and the Class Meetings were convened in accordance with the requirements of the relevant laws and regulations of the PRC and the Articles of Association, and the poll results of the AGM and the Class Meetings are lawful and valid.

The Board is pleased to announce that all the resolutions proposed at the AGM and the Class Meetings as set out in the Notices were duly passed by the Shareholders by way of poll at the AGM and the Class Meetings.

POLL RESULTS OF THE AGM

The poll results in respect of all the resolutions proposed at the AGM are as follows:

ORDINARY RESOLUTIONS		NO. OF SHARES VOTED (%)		
		FOR	AGAINST	ABSTAIN
1.	To consider and approve the resolution on the report of the Board of Directors of the Company for the year 2022.	1,283,981,586 (100%)	0 (0%)	0 (0%)
2.	To consider and approve the resolution on the report of the Board of Supervisors of the Company for the year 2022.	1,283,981,586 (100%)	0 (0%)	0 (0%)
3.	To consider and approve the resolution on the annual report of the Group for the year 2022.	1,283,981,586 (100%)	0 (0%)	0 (0%)
4.	To consider and approve the resolution on the financial accounts report of the Group for the year 2022.	1,283,981,586 (100%)	0 (0%)	0 (0%)
5.	To consider and approve the resolution on the financial budget of the Group for the year 2023.	1,283,789,022 (99.99%)	192,564 (0.01%)	0 (0%)
6.	To consider and approve the resolution on the annual profit distribution plan of the Company for the year 2022.	1,283,981,586 (100%)	0 (0%)	0 (0%)
7.	To consider and approve the re-appointment of PricewaterhouseCoopers as the auditor of the Company for 2023, for a term commencing from the date of approval at the AGM until the conclusion of the 2023 annual general meeting of the Company, and authorize the Board to determine the specific matters in relation to such re-appointment, including but not limited to their remunerations.	1,283,981,586 (100%)	0 (0%)	0 (0%)
SPECIAL RESOLUTIONS		NO. OF SHARES VOTED (%)		
		FOR	AGAINST	ABSTAIN
8.	To consider and approve the proposed amendments to the articles of association of the Company in respect of the Trial Measures.	1,283,789,022 (99.99%)	192,564 (0.01%)	0 (0%)
9.	To consider and approve the proposed amendments to the articles of association of the Company in respect of the proposed issue of A Shares.	1,283,789,022 (99.99%)	192,564 (0.01%)	0 (0%)
10.	To consider and approve the resolution on the grant of a general mandate to the Board to issue shares.	1,283,789,022 (99.99%)	192,564 (0.01%)	0 (0%)

As more than one-half of the votes were cast in favour of each of the resolutions numbered 1 to 7 above, these resolutions were duly passed as ordinary resolutions of the Company.

As more than two-thirds of the votes were cast in favour of the resolutions numbered 8 to 10 above, these resolutions were duly passed as special resolutions of the Company.

POLL RESULTS OF THE CLASS MEETING OF H SHAREHOLDERS

The poll results in respect of all the resolutions proposed at the Class Meeting of H Shareholders are as follows:

SPECIAL RESOLUTIONS		NO. OF SHARES VOTED (%)		
		FOR	AGAINST	ABSTAIN
1.	To consider and approve the proposed amendments to the articles of association of the Company in respect of the Trial Measures.	1,230,839,136 (99.98%)	193,564 (0.02%)	0 (0%)
2.	To consider and approve the proposed amendments to the articles of association of the Company in respect of the proposed issue of A Shares.	1,230,839,136 (99.98%)	193,564 (0.02%)	0 (0%)

As more than two-thirds of the votes were cast in favour of the resolutions numbered 1 and 2 above, these resolutions were duly passed as special resolutions of the Company.

POLL RESULTS OF THE CLASS MEETING OF DOMESTIC SHAREHOLDERS

The poll results in respect of all the resolutions proposed at the Class Meeting of Domestic Shareholders are as follows:

SPECIAL RESOLUTIONS		NO. OF SHARES VOTED (%)		
		FOR	AGAINST	ABSTAIN
1.	To consider and approve the proposed amendments to the articles of association of the Company in respect of the Trial Measures.	52,949,886 (100%)	0 (0%)	0 (0%)
2.	To consider and approve the proposed amendments to the articles of association of the Company in respect of the proposed issue of A Shares.	52,949,886 (100%)	0 (0%)	0 (0%)

As more than two-thirds of the votes were cast in favour of the resolutions numbered 1 and 2 above, these resolutions were duly passed as special resolutions of the Company.

Notes:

1. As at the date of the AGM and the Class Meetings, the total number of issued ordinary Shares was 1,659,444,838 Shares (including 1,605,176,474 H Shares and 54,268,364 Domestic Shares), which represented the total number of Shares entitling the Shareholders to attend and vote on the proposed resolutions at the AGM and the Class Meetings.
2. There were no Shareholders, who, pursuant to Rule 13.40 of the Listing Rules, were required to abstain from voting in favour of any of the proposed resolutions at the AGM and the Class Meetings, nor were there any Shareholders who were required under the Listing Rules to abstain from voting.
3. None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the AGM and the Class Meetings.

4. The total number of issued Shares held by the Shareholders in person or their proxies who have attended the AGM and are entitled to vote is 1,283,981,586 Shares, representing approximately 77.37% of the total number of issued Shares as at the date of the AGM.
5. The total number of issued H Shares held by the H Shareholders in person or their proxies who have attended the Class Meeting of H Shareholders and are entitled to vote is 1,231,032,700 H Shares, representing approximately 76.69% of the total number of issued H Shares as at the date of the Class Meeting of H Shareholders.
6. The total number of issued Domestic Shares held by the Shareholders in person or their proxies who have attended the Class Meeting of Domestic Shareholders and are entitled to vote is 52,949,886 Domestic Shares, representing approximately 97.57% of the total number of issued Domestic Shares as at the date of the Class Meeting of Domestic Shareholders.
7. The Company's H Shares registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM and the Class Meetings for the purpose of vote-taking.
8. All Directors attended the AGM and the Class Meetings in person or via electronic means.

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

The Board hereby announces that the special resolutions numbered 8 and 9 as set out in the notice of the AGM, the special resolutions numbered 1 and 2 as set out in the notice of the Class Meeting of H Shareholders, and the special resolutions numbered 1 and 2 as set out in the notice of the Class Meeting of Domestic Shareholders, in relation to (i) the proposed amendments to the Articles in respect of the Trial Measures and (ii) the proposed amendments to the Articles in respect of the proposed issue of A Shares were duly passed as special resolutions at the AGM and the Class Meetings. The amendments to the Articles in respect of the Trial Measures would come into effect upon the draft amendments to the Listing Rules in Appendix II to the consultation paper "Rule Amendments Following Mainland China Regulation Updates and Other Proposed Rule Amendments Relating to the PRC Issuers" published on February 24, 2023 by the Stock Exchange being fully implemented and becoming effective (the "**Listing Rule Amendments**"). The amendments to the Articles in respect of the proposed issue of A Shares would come into effect after the completion of the issue of A Shares and listing on the Sci-Tech Board. The Company will make consequential change to the number of the relevant articles as a result of the adoption of the amendments to the Articles. Upon the completion of the Listing Rule Amendments and the issue of A Shares and listing on the Sci-Tech Board and the relevant amendments coming into effect, the full text of the amended Articles will be published on the websites of the Stock Exchange and the Company respectively.

By order of the Board
Lepu Biopharma Co., Ltd.
Dr. Pu Zhongjie
Chairman of the Board and Executive Director

Shanghai, the PRC, June 15, 2023

As at the date of this announcement, the Board comprises Dr. Pu Zhongjie (Chairman), Dr. Sui Ziye (Chief Executive Officer) and Dr. Hu Chaohong (Co-Chief Executive Officer) as executive Directors; Mr. Lin Xianghong, Mr. Yang Hongbing and Ms. Pu Jue, as non-executive Directors; and Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua as independent non-executive Directors.